You're leaving Lundbeck Australia
You are now leaving lundbeck.com/au. Please note that the information contained in the site you are linking to may not be fully compliant with the Australian regulatory environment and that product related information should be checked against the corresponding Australian consumer medicine information or by asking your doctor. Any information provided should be discussed with your health care professional and does not replace the advice and treatment of your doctor.
At a Glance
Lundbeck in Brief
Lundbeck is a global pharmaceutical company specialized in developing innovative treatments for brain diseases. For more than 70 years, millions of people have been treated with our products and our development and distribution of pioneering therapies continues to make a difference to people worldwide.
Lundbeck in numbers
1915
Lundbeck was founded by Hans Lundbeck in Copenhagen more than 100 years ago.
5,800
We are approximately 5,800 employees worldwide.
70%
Our largest shareholder is the Lundbeck Foundation owning approximately 70%.
100
Our products are registered in more than 100 countries globally.
70
Number of years that we have been building our neuroscience expertise.
50 m
Our portfolio of products reaches more than 50 million people yearly.
Global presence
We are headquartered in Denmark and located in more than 50 countries around the world. We have production facilities in Denmark, France and Italy and research centers in Denmark and US.
We have employees in more than 50 countries and employ approximately 5,800 people across the value chain.
Ownership
In 1999, Lundbeck’s shares were listed on Nasdaq Copenhagen. Our largest shareholder is the Lundbeck Foundation, which holds approximately 70% of the shares. The Foundation annually grants about DKK 500 million to support medical research and educational and communication activities.
Key financial figures
Our 2019 revenue reached a total of DKK 17,036 million.
Our largest markets are US, China, Canada, Spain, Italy, France, Japan, Korea, Australia and Brazil.
In 2019, our total revenue from strategic brands was DKK 9,385 million.